Article summary
Psychedelic biotechnology company Bright Minds Biosciences recently announced that it has dosed the first patient in a Phase I trial (NCT 05397041) for its lead product, BMB-101, for the treatment of Dravet Syndrome and other medical indications. The company which focuses on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain confirmed the launch of the trial which is being conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-time in-human studies. BMB-101 is a next-generation, 5-HT2C selective and biased agonist that exhibits compelling behavioral and The post Bright Minds Biosciences Announce Dosing of First Patient in Phase 1 Clinical Trial of BMB-101 for Dravet Syndrome appeared first on Psychedelic Chronicle.
Continue to the original publication for the complete article.